The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria
Status:
Unknown status
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, prospective, interventional study. It does not have a control
group. All participants will receive 160 mg valsartan for 8 weeks. Among them, the patients
with persistent proteinuria (defined as proteinuria more than 1 g/g after 8 weeks treatment
of valsartan) will receive 320 mg valsartan for further 16 weeks. Participants who did not
receive any ACEI or ARB previously will have a titration period for 4 weeks (80 mg for 4
weeks, 160 mg for 4 weeks, and then 320 mg for 16 weeks).
The investigators will evaluate the change of urinary angiotensinogen excretion between at
baseline, at 8 weeks, and 24 weeks.